This article is more than 5 years old. Information may no longer be current.

Modified anti-VEGF dosing regimen may be sufficient for myopic CNV

Retina. 2011;31(5):880-886.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

For the treatment of myopic choroidal neovascularization, a regimen consisting of a single injection of bevacizumab followed by as-needed dosing may require fewer injections and achieve similar visual outcomes as three injections followed by as-needed dosing, a study found.

In the retrospective, consecutive, interventional case series, 19 eyes were treated with a single injection of Avastin (bevacizumab, Genentech) and 12 eyes were treated with three injections; initial injections in both groups were followed by as-needed dosing.

Best corrected visual acuity improved significantly for the two groups at 3, 6 and 12 months, and mean gain in visual acuity did not differ significantly between the groups at any interval.

The single injection plus as-needed treatment required significantly fewer injections, with 79% of eyes requiring only one or two injections. Meanwhile, the rate of recurrence as well as the rate of neovascularization persistence did not differ between groups.

Because the study duration was only 1 year, the authors suggested further analysis to determine the long-term safety and efficacy of this treatment.